Predictive Oncology Files Q2 2024 10-Q, Reports Warrant Events
Ticker: AGPU · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 1446159
Sentiment: neutral
Topics: 10-Q, subsequent-event, warrants
Related Tickers: POAI
TL;DR
POAI Q2 10-Q out: warrants issued July 25th. Watch dilution.
AI Summary
Predictive Oncology Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities. Key events include the issuance of placement agent warrants and Series A and B warrants on July 25, 2024, which are considered subsequent events.
Why It Matters
This filing provides investors with an update on Predictive Oncology's financial health and operational developments, including significant warrant issuances that could impact future share structure.
Risk Assessment
Risk Level: medium — The company has undergone name changes and is involved in warrant issuances, which can indicate potential dilution and financial restructuring.
Key Players & Entities
- Predictive Oncology Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240813 (date) — Filing date
- Precision Therapeutics Inc. (company) — Former company name
- Skyline Medical Inc. (company) — Former company name
- 20180314 (date) — Date of name change
- 2024-07-25 (date) — Date of subsequent warrant events
FAQ
What was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing was for the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 13, 2024.
What are some of the former names of Predictive Oncology Inc.?
Predictive Oncology Inc. was formerly known as Precision Therapeutics Inc. and Skyline Medical Inc.
What significant subsequent events are mentioned in the filing related to warrants?
The filing mentions subsequent events on July 25, 2024, involving the issuance of placement agent warrants and Series A and Series B warrants.
What is the SIC code for Predictive Oncology Inc.?
The Standard Industrial Classification (SIC) code for Predictive Oncology Inc. is 3842, related to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 4,371 words · 17 min read · ~15 pages · Grade level 16.5 · Accepted 2024-08-13 17:00:32
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Marke
Filing Documents
- poai20240630_10q.htm (10-Q) — 926KB
- ex_709256.htm (EX-31.1) — 12KB
- ex_709257.htm (EX-31.2) — 12KB
- ex_709258.htm (EX-32.1) — 6KB
- 0001171843-24-004757.txt ( ) — 5374KB
- poai-20240630.xsd (EX-101.SCH) — 53KB
- poai-20240630_def.xml (EX-101.DEF) — 349KB
- poai-20240630_lab.xml (EX-101.LAB) — 306KB
- poai-20240630_pre.xml (EX-101.PRE) — 380KB
- poai-20240630_cal.xml (EX-101.CAL) — 39KB
- poai20240630_10q_htm.xml (XML) — 809KB
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2024, AND DECEMBER 31, 2023 4 CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024, AND 2023 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS ' EQUITY FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024, AND 2023 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2024, AND 2023 8 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9
MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM 2. MANAGEMENT ' S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 19
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 24
CONTROLS AND PROCEDURES
ITEM 4. CONTROLS AND PROCEDURES 24
OTHER INFORMATION
PART II. OTHER INFORMATION
LEGAL PROCEEDINGS
ITEM 1. LEGAL PROCEEDINGS 25
RISK FACTORS
ITEM 1A. RISK FACTORS 25
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 25
DEFAULTS UPON SENIOR SECURITIES
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 25
MINE SAFETY DISCLOSURES
ITEM 4. MINE SAFETY DISCLOSURES 25
OTHER INFORMATION
ITEM 5. OTHER INFORMATION 25
EXHIBITS
ITEM 6. EXHIBITS 26
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS PREDICTIVE ONCOLOGY INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 5,331,770 $ 8,728,660 Accounts receivable 387,040 333,697 Inventories 568,215 494,374 Prepaid expense and other assets 597,724 521,700 Total current assets 6,884,749 10,078,431 Property and equipment, net 910,211 1,233,910 Intangibles, net 238,731 252,457 Lease right-of-use assets 2,432,339 2,728,355 Other long-term assets 121,096 124,096 Total assets $ 10,587,126 $ 14,417,249 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,563,023 $ 1,342,027 Note payable 276,932 150,408 Accrued expenses and other liabilities 1,946,893 1,631,702 Derivative liability 8 1,376 Contract liabilities 269,943 308,091 Lease liability 561,712 517,427 Total current liabilities 4,618,511 3,951,031 Other long-term liabilities 13,661 5,459 Lease liability – net of current portion 1,860,983 2,188,979 Total liabilities 6,493,155 6,145,469 Stockholders' equity: Preferred stock, 20,000,000 shares authorized inclusive of designated below Series B Convertible Preferred Stock, $ .01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of June 30, 2024, and December 31, 2023 792 792 Common stock, $ .01 par value, 200,000,000 shares authorized, 5,708,876 and 4,062,853 shares outstanding as of June 30, 2024, and December 31, 2023, respectively 57,089 40,629 Additional paid-in capital 179,198,077 175,992,242 Accumulated deficit ( 175,161,987 ) ( 167,761,883 ) Total stockholders' equity 4,093,971 8,271,780 Total liabilities and stockholders' equity $ 10,587,126 $ 14,417,249 See accompanying notes to unaudited condensed consolidated financial statements. 4 PREDICTIVE ONCOLOGY INC. CONDENSED C